BackgroundAllopurinol has vascular antioxidant effects and participates in purinergic signalling within muscle. We tested whether allopurinol could improve skeletal muscle energetics and physical function in older people with impaired physical performance.
MethodsWe conducted a randomised, double blind, parallel group, placebo-controlled trial, comparing 20 weeks of allopurinol 600mg once daily versus placebo. We recruited community-dwelling participants aged 65 and over with baseline six-minute walk distance of <400m and no contraindications to MRI scanning. Outcomes were measured at baseline and 20 weeks. The primary outcome was post-exercise phosphocreatine recovery rate measured using 31 P magnetic resonance spectroscopy of the calf. Secondary outcomes included six-minute walk distance, short physical performance battery (SPPB), lean body mass measured by bioimpedance, endothelial function and quality of life. Results 124 participants were randomised, mean age 80 (SD 6) years. 59 (48%) were female, baseline six-minute walk distance was 293m (SD 80m) and baseline SPPB was 8.5 (SD 2.0). Allopurinol did not significantly improve phosphocreatine recovery rate (treatment effect Jones, Thomas et al. "Analysis of throwing power for megasonic assisted electrodeposition of copper inside THVs". Ultrasonics. 2020.